Science & Medicine | Uganda Begins Phase I Trial of Perinatal HIV
Vaccine [Oct 19, 2006]
Uganda last week began enrollment of Phase I trials of a
perinatal HIV vaccine that aims to prevent mother-to-child HIV
transmission, Uganda's Daily Monitor reports (Nabayunga, Daily Monitor,
10/18). The Makerere University-Johns Hopkins University Research
Collaboration has enrolled 50 infants born to HIV-positive women who
attended the Mulago Antenatal care clinic into a perinatal HIV vaccine
trial (Kaiser Daily HIV/AIDS Report, 10/11). Francis Mmiiro, lead
investigator for the MU-JHU collaboration, on Oct. 13 at a press
conference said the first infant was given the vaccine on Thursday,
initiating the first phase of the study. During Phase I, infants will
receive the vaccine at birth and at one, two and three months of age and
will be followed for two years, the Monitor reports. Phase II of the
study will involve more infants and aims to determine if the vaccine is
safe on a larger scale. Phase III, the final trial, will involve even
more infants, the Monitor reports. Mother-to-child HIV transmission
"occurs during pregnancy, labor and through breast-feeding, which makes
this vaccine a major priority for babies born to HIV infected women
because they are exposed to the virus," Mmiiro said, adding that safe
breast-feeding is possibly the most important challenge in preventing
mother-to-child HIV transmission in sub-Saharan Africa (Daily Monitor,
10/18).
_______________________________________________
Post message:
pronu...@healthnet.orgSubscribe:
pronut-...@healthnet.orgUnsubscribe:
pronut-h...@healthnet.orgHelp:
pronut-h...@healthnet.orgInfo & archives:
http://list.healthnet.org/mailman/listinfo/pronut-hiv